NFKB1 and breast carcinoma: To confirm the role of azilsartan in targeting and inhibiting NF-kB pathway with subsequent initiation of apoptosis, MCF-7 and MDA-MB-231 cancer cells were stimulated with the inflammatory cytokine TNFα, which was reported to activate NF-kB pathway, resulting in further invasion and metastasis of breast cancer cells [65].